Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02187471 · ClinicalTrials.gov registry record · Phase 3
Treatment of Pain Associated With Fibromyalgia
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,301
- Enrollment target
NCT02187471 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 1,301 participants.
The verdict
NCT02187471, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,301 participants
- Enrollment target
Study Summary
The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the subject that best describes his or her worst pain over the previous 24 hours.
Interventions
- DRUG Placebo tablet
- DRUG Pregabalin
- DRUG Placebo capsule
- DRUG DS-5565
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,301 participants |
| Start Date | 2015-01-16 |
| Est. Completion | 2017-01-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02187471
The ClinicalTrials.gov registry entry for NCT02187471 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo tablet is the first listed.
NCT02187471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02187471 about?
NCT02187471 is a clinical study titled "Treatment of Pain Associated With Fibromyalgia". The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the subject that best describes his or her worst pain over ...
What is the current status of trial NCT02187471?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,301 participants. The study started on 2015-01-16. Estimated completion is 2017-01-12.
What interventions are being tested in trial NCT02187471?
The interventions under investigation include: Placebo tablet (DRUG), Pregabalin (DRUG), Placebo capsule (DRUG), DS-5565 (DRUG).
Who is sponsoring clinical trial NCT02187471?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.